Cheng et al. reported that metformin, a commonly utilized medication for diabetes, worked synergistically to boost the antitumor effects of lenvatinib in HCC by promoting apoptosis and triggering cell cycle arrest through the modulation of the AKT-Forkhead box protein O3 (FOXO3) pathway 101. This evidence concerns the gene FOXO3 and hepatocellular carcinoma.